{"nctId":"NCT00150813","briefTitle":"Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.","startDateStruct":{"date":"2005-08-10","type":"ACTUAL"},"conditions":["Epilepsy, Tonic-clonic"],"count":66,"armGroups":[{"label":"Levetiracetam","type":"EXPERIMENTAL","interventionNames":["Drug: Levetiracetam"]}],"interventions":[{"name":"Levetiracetam","otherNames":["Keppra"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects with a confirmed diagnosis of epilepsy.\n* Subjects having experienced in the past unprovoked partial seizures (IA, IB, IC with clear focal origin),or generalized tonic-clonic seizures (without clear focal origin), that are classifiable according to the International Classification of Epileptic Seizures\n* Subjects having participated in the previous double-blind monotherapy trial (N01061 \\[NCT00150735\\] or N01093 \\[NCT00150787\\]).\n* Male/female subjects (\\>= 16 years).\n\nExclusion Criteria:\n\n\\- Need for an additional Antiepileptic Drug (AED).","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Participants With Treatment Emergent Adverse Events","description":"An Adverse Event (AE) is any untoward medical occurrence (eg, noxious or pathological changes) in a subject or clinical investigation subject compared with pre-existing conditions, that occurs during any period of a clinical trial. An AE is defined as being independent of assumption of any causality (eg, to study or concomitant medication, primary or concomitant disease, or study design).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":66},"commonTop":[]}}}